Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.02 (+0.20%)
At close: Aug 20, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMII) Operating Expenses (2025)

Drugs Made In America Acquisition (DMII) posted quarterly Operating Expenses of $235472.0 for Q4 2025, up 51.42% quarter-over-quarter from $155513.0 in Q3 2025.

Drugs Made In America Acquisition (DMII) Operating Expenses (2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Operating Expenses for 1 consecutive years, with $235472.0 the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 Launch Two Acquisition 557.86 Mn 557.86 Mn - 194,528.00
2 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - 112,227.00
3 Cantor Equity Partners IV 467.55 Mn 467.55 Mn - 174,182.00
4 GP-Act III Acquisition 401.06 Mn 401.06 Mn - 1.47 Mn
5 Aldel Financial 397.49 Mn 397.49 Mn - 115,742.00
6 Gores Holdings X 381.05 Mn 380.85 Mn - -
7 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - 390,784.00
8 Blue Water Acquisition Corp. III 342.12 Mn 342.08 Mn - 197,949.00
9 Berto Acquisition 313.96 Mn 313.81 Mn - 1.62 Mn
10 New Providence Acquisition Corp. III 313.81 Mn 313.81 Mn - 531,206.00

Historic Data

Download Data
DateValue
Dec 31, 2025 235,472.00
Sep 30, 2025 155,513.00